RJA
TRVI icon

Raymond James & Associates’s Trevi Therapeutics TRVI Stock Holding History

Raymond James & Associates’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$319K Buy
95,383
+85,383
+854% +$254K ﹤0.01% 3372
2024
Q2 		$29.8K Hold
10,000
– – ﹤0.01% 3851
2024
Q1 		$34.5K Buy
+10,000
New +$22.3K ﹤0.01% 3835

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Raymond James & Associates's TRVI Position: Q3 2024 in Review

Raymond James & Associates increased its Trevi Therapeutics (TRVI) stake by 854% in Q3 2024, buying an estimated $254K and bringing the position to 95,383 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #3372.

Raymond James & Associates first reported a position in TRVI in Q1 2024 and has held it in 3 quarters since. 93 funds tracked by Wall St. Rank hold TRVI as of Q3 2024.

  • Raymond James & Associates held 95,383 shares of Trevi Therapeutics worth $319K as of Q3 2024.
  • Raymond James & Associates bought 85,383 Trevi Therapeutics shares in Q3 2024, an estimated $254K.
  • Trevi Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3372 holding.
  • Raymond James & Associates first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 93 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.